![Christopher Taylor](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Christopher Taylor worked as Vice President-Investor Relations & Communications at Alaunos Therapeutics, Inc. Served as VP-Investor Relations & Corporate Communications at Agios Pharmaceuticals, Inc. From 2020 to 2023, held the position of VP-Investor Relations & Corporate Communications at Codiak BioSciences, Inc.
Ehemalige bekannte Positionen von Christopher Taylor
| Unternehmen | Position | Ende |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Investor Relations Kontakt | 01.08.2025 |
| CODIAK BIOSCIENCES | Investor Relations Kontakt | 01.06.2023 |
| ALAUNOS THERAPEUTICS, INC. | Investor Relations Kontakt | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
3
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Agios Pharmaceuticals, Inc.
 Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Alaunos Therapeutics, Inc.
 Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
